#USA #Princeton #Biopharmaceutical #Soligenix #HyBryte

Soligenix at H.C. Wainwright Investment Conference

Soligenix, Inc., a late-stage biopharmaceutical company trading on Nasdaq under the ticker SNGX, has recently announced its invitation to present at the upcoming H.C. Wainwright 27th Annual Global Investment Conference. This significant event is set to take place from September 8 to 10, 2025, and will serve as a platform for major discussions in investment opportunities in the biopharmaceutical sector.

Presentation Details

Dr. Christopher J. Schaber, the President and Chief Executive Officer of Soligenix, will take the stage to deliver a corporate presentation. This comes as part of Soligenix's commitment to keeping stakeholders updated on the progress of their innovative therapeutic solutions for rare diseases with high medical need. The presentation itself is scheduled to be available for attendees on-demand starting from 7:00 AM ET on September 5, 2025, giving those interested ample time to engage with the material in a convenient format.

The H.C. Wainwright Global Investment Conference will feature presentations, one-on-one meetings, and networking opportunities designed to connect companies with investors. Key members from Soligenix's management team are expected to participate in one-on-one meetings, enabling registered attendees to discuss the company’s vision, strategic initiatives, and the progress of clinical programs directly.

About Soligenix

Soligenix focuses on developing and commercializing therapeutic products for rare diseases that currently lack effective treatment options. Their main product, HyBryte™ (SGX301), is in the advanced stages of development as a novel photodynamic therapy utilizing safe visible light for the management of cutaneous T-cell lymphoma (CTCL). The company has recently completed a second Phase 3 clinical trial, and following successful results, it will seek regulatory approvals to commercialize this innovative treatment globally.

In addition to HyBryte™, Soligenix’s development pipeline includes programs targeting psoriasis with synthetic hypericin (SGX302) and utilizing their first-in-class innate defense regulator (IDR) technology, such as dusquetide (SGX942) for treating inflammatory diseases like oral mucositis associated with head and neck cancers.

Soligenix also emphasizes public health solutions with their development programs for vaccines against bioterror threats, such as granules for ricin toxin and viruses that cause epidemics, including the filoviruses and COVID-19. Their proprietary heat stabilization platform, known as ThermoVax®, is incorporated into these vital projects.

These advancements have gained interest from government bodies, leading to support via grants and contracts from agencies such as the National Institute of Allergy and Infectious Diseases (NIAID) and the Defense Threat Reduction Agency (DTRA).

Looking Ahead

The invitation to present at this major conference reflects the strong position Soligenix is carving out within the biopharmaceutical sector. With several promising therapies nearing crucial regulatory steps, the company is gearing up to deliver innovative solutions that address unmet needs in rare medical conditions—making the upcoming investment conference a pivotal moment in their journey.

For more information regarding Soligenix's developments and initiatives, interested parties can visit their official website at Soligenix. Additionally, stay updated by following them on LinkedIn and Twitter at @Soligenix_Inc.